Overview

InclisiRan for Early Passivation of VulneRable AthEroSclerotic PlaqueS in Patients with Acute Coronary SyndromesREPRESS

Status:
NOT_YET_RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
In this prospective, multicenter, open-label randomized controlled trial, 180 patients with ACS are randomized in a 1:1 ratio to either "inclisiran early" intensified therapy (early adding inclisiran to moderate-intensity statin therapy) group or guideline-directed medical therapy group for 12 months. Patients experience serial OCT of the non-culprit, non-flow-limiting arteries (target vessels) at baseline (culprit lesion procedure on admission) and at 12 months. The primary endpoint is the percentage of patients with vulnerable plaques in target vessels at 1 year post randomization.
Phase:
NA
Details
Lead Sponsor:
West China Hospital
Treatments:
ALN-PCS